Verastem gains on positive ovarian cancer drug results
VSTM•Verastem said its avutometinib and defactinib combination showed an 18% response rate in patients with recurrent low-grade serous ovarian cancer whose tumors lack three key mutations; patients went a median 13 months without disease worsening.
1. Trial results
Verastem said the drug combination produced an 18% response rate among patients with recurrent low-grade serous ovarian cancer whose tumors lack three key mutations. Patients went a median 13 months without disease worsening, and the company said the combination showed stronger results than conventional care.
2. Safety and presentation
Potential safety risks include eye problems, serious skin reactions, liver damage and muscle injury, requiring regular monitoring. The results are due to be presented Friday at the IGCS 2026 meeting in Montreal.
